These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 2684096)
61. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. Lustig S; Fogg C; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B J Virol; 2005 Nov; 79(21):13454-62. PubMed ID: 16227266 [TBL] [Abstract][Full Text] [Related]
62. Protective immune responses to the E and NS1 proteins of Murray Valley encephalitis virus in hybrids of flavivirus-resistant mice. Hall RA; Brand TN; Lobigs M; Sangster MY; Howard MJ; Mackenzie JS J Gen Virol; 1996 Jun; 77 ( Pt 6)():1287-94. PubMed ID: 8683218 [TBL] [Abstract][Full Text] [Related]
63. Lansing poliovirus infection in mice: antibody demonstrable by enzyme-linked immunosorbent assay (ELISA) and immunoprecipitation but not by neutralization. Jubelt B; Lipton H J Neuroimmunol; 1987 Feb; 14(1):109-21. PubMed ID: 3027122 [TBL] [Abstract][Full Text] [Related]
64. Humoral and cell-mediated immune responses in humans before and after revaccination with vaccinia virus. Møller-Larsen A; Haahr S Infect Immun; 1978 Jan; 19(1):34-9. PubMed ID: 624594 [TBL] [Abstract][Full Text] [Related]
69. Meningeal exudate cells in vaccinia meningitis of mice: role of local T cells. Morishima T; Hayashi K Infect Immun; 1978 Jun; 20(3):752-9. PubMed ID: 352957 [TBL] [Abstract][Full Text] [Related]
70. The effect of cyclophosphamide on intracerebral vaccinia virus infection in Balb/C mice. Ginsberg AH; Johnson KP Exp Mol Pathol; 1977 Dec; 27(3):285-94. PubMed ID: 923746 [No Abstract] [Full Text] [Related]
71. Mechanism of induction of cell-mediated immunity to virus infections: in vitro inhibition of intracellular multiplication of mouse adenovirus by immune spleen cells. Hamada C; Uetake H Infect Immun; 1975 May; 11(5):937-43. PubMed ID: 164414 [TBL] [Abstract][Full Text] [Related]
73. Immune effector cell activity in canines: failure to demonstrate genetic restriction in direct antiviral cytotoxicity. Ho CK; Babiuk LA; Rouse BT Infect Immun; 1978 Jan; 19(1):18-25. PubMed ID: 304843 [TBL] [Abstract][Full Text] [Related]
74. Viral spread in the presence of neutralizing antibody: mechanisms of persistence in foamy virus infection. Hooks JJ; Burns W; Hayashi K; Geis S; Notkins AL Infect Immun; 1976 Nov; 14(5):1172-8. PubMed ID: 185150 [TBL] [Abstract][Full Text] [Related]
75. The role of viral glycoproteins in mumps-virus-dependent lymphocyte-mediated cytotoxicity in vitro. Härfast B; Orvell C; Alsheikhly A; Andersson T; Perlmann P; Norrby E Scand J Immunol; 1980; 11(4):391-400. PubMed ID: 7384752 [TBL] [Abstract][Full Text] [Related]
76. Characterization and structural localization of the reovirus lambda 3 protein. Cashdollar LW Res Virol; 1994; 145(5):277-85. PubMed ID: 7839005 [TBL] [Abstract][Full Text] [Related]
77. Soluble antigens of vaccinia-infected mammalian cells. II. Time course of synthesis of soluble antigens and virus structural proteins. Wilcox WC; Cohen GH J Virol; 1967 Jun; 1(3):500-8. PubMed ID: 5623969 [TBL] [Abstract][Full Text] [Related]
78. Vaccinia virus infection of the central nervous system in X-irradiated mice. Simon J; Werner GT Infect Immun; 1979 Sep; 25(3):1035-42. PubMed ID: 500184 [TBL] [Abstract][Full Text] [Related]
79. The influence of virus structure on antibody responses and virus serotype formation. Bachmann MF; Zinkernagel RM Immunol Today; 1996 Dec; 17(12):553-8. PubMed ID: 8991286 [No Abstract] [Full Text] [Related]
80. Design and Engineering of Deimmunized Vaccinia Viral Vectors. Song K; Viskovska M Biomedicines; 2020 Nov; 8(11):. PubMed ID: 33187060 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]